Report cover image

Australia and New Zealand Anemia in Pregnancy Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Feb 13, 2024
Length 120 Pages
SKU # EMAR18558315

Description

Australia and New Zealand Anemia in Pregnancy Market Report and Forecast 2024-2032


Australia and New Zealand Anemia in Pregnancy Market Report and Forecast 2024-2032

Australia and New Zealand Anemia in Pregnancy Market Outlook

The Australia and New Zealand anemia in pregnancy market size is anticipated to grow at a CAGR of 8.6% during the forecast period of 2024-2032, driven by the rising incidence of pregnancies across the region.

Anemia in Pregnancy: Introduction

Anemia in pregnancy is a common condition where the mother's blood lacks enough healthy red blood cells to carry adequate oxygen to her body and the fetus. It's often caused by iron deficiency, as the demand for iron and other nutrients increases to support the growing fetus and placenta. Symptoms can include fatigue, weakness, and shortness of breath. Managing anemia is crucial, as severe cases can lead to premature birth and low birth weight.

Key Trends in the Australia and New Zealand Anemia in Pregnancy Market

Enhanced focus on early and regular screening for anemia during prenatal visits to ensure timely diagnosis and intervention.

Rising demand for iron supplements and fortified foods to prevent and treat iron-deficiency anemia among pregnant women.

Growing efforts to educate women about the importance of nutrition and iron-rich diets during pregnancy, emphasizing preventive care.

Development and adoption of advanced, patient-friendly iron supplements and therapies, with a focus on minimizing side effects and improving absorption.

Integration of care between obstetricians, midwives, and nutritionists to provide holistic and individualized care for pregnant women with anemia.

Increased support from global health organizations for programs aimed at reducing anemia in pregnancy, especially in regions with high prevalence rates.

Australia and New Zealand Anemia in Pregnancy Market Segmentation

Market Breakup by Cause
  • Folic Acid Deficiency
  • Iron Deficiency
  • Vitamin B12 Deficiency
  • Others
Market Breakup by Treatment
  • Iron Products
  • Folic Acid Supplementation
  • Others
Market Breakup by Weeks
  • < 13 Weeks
  • 13-27 Weeks
  • ≥28 Weeks
Market Breakup by Route of Administration
  • Oral
  • Intravenous
  • Intramuscular
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Market Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others
Market Breakup by Country
  • Australia
  • New Zealand
Australia and New Zealand Anemia in Pregnancy Market Overview

In Australia, the approach to managing anemia in pregnancy is integrated and patient focused. Routine antenatal screening programs to detect and treat anemia early in pregnancy, minimizing complications. Emphasis on public health education regarding nutrition, focusing on diets rich in iron, folate, and other essential nutrients, to prevent anemia. Widespread availability of iron supplements and other nutritional aids provided through healthcare programs. Ongoing research and updated clinical guidelines to optimize the management of anemia in pregnancy, ensuring evidence-based care.

In New Zealand, the focus is on accessible and quality healthcare to address anemia in pregnancy. Universal healthcare system provides accessible antenatal care, including anemia screening and treatment. Healthcare services tailored to meet the diverse cultural needs of the population, ensuring appropriate and effective management of anemia in pregnancy. Integrated care approach involving midwives, GPs, and obstetricians, ensuring consistent and holistic care for pregnant women. Strong health promotion strategies focusing on preventive care, including nutritional education and awareness about anemia during pregnancy.

Australia and New Zealand Anemia in Pregnancy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Viatris Inc.
  • Aspen Pharmacare Australia Pty Ltd
  • PharmaCare Laboratories Australia
  • AFT Pharmaceuticals
  • Bayer AG
  • A Nelson & Co Ltd
  • BLACKMORES
  • Care Pharma
  • Amgen Inc.
  • Hoffmann-La Roche Ltd.
  • AMAG Pharmaceuticals
  • Rockwell Medical
  • Vifor Pharma Management Ltd.
  • Janssen Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

120 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand Anemia in Pregnancy Market Overview
3.1 Australia and New Zealand Anemia in Pregnancy Market Historical Value (2017-2023)
3.2 Australia and New Zealand Anemia in Pregnancy Market Forecast Value (2024-2032)
4 Australia and New Zealand Anemia in Pregnancy Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Australia and New Zealand Anemia in Pregnancy Market Segmentation
5.1 Australia and New Zealand Anemia in Pregnancy Market by Cause
5.1.1 Market Overview
5.1.2 Folic Acid Deficiency
5.1.3 Iron Deficiency
5.1.4 Vitamin B12 Deficiency
5.1.5 Others
5.2 Australia and New Zealand Anemia in Pregnancy Market by Treatment
5.2.1 Market Overview
5.2.2 Iron Products
5.2.3 Folic Acid Supplementation
5.2.4 Others
5.3 Australia and New Zealand Anemia in Pregnancy Market by Weeks
5.3.1 Market Overview
5.3.2 < 13 Weeks
5.3.3 13-27 Weeks
5.3.4 ≥28 Weeks
5.4 Australia and New Zealand Anemia in Pregnancy Market by Route of Administration
5.4.1 Market Overview
5.4.2 Oral
5.4.3 Intravenous
5.4.4 Intramuscular
5.5 Australia and New Zealand Anemia in Pregnancy Market by Distribution Channel
5.5.1 Market Overview
5.5.2 Hospital Pharmacy
5.5.3 Retail Pharmacy
5.5.4 Online Pharmacy
5.5.5 Others
5.6 Australia and New Zealand Anemia in Pregnancy Market by End User
5.6.1 Market Overview
5.6.2 Hospitals
5.6.3 Specialty Clinics
5.6.4 Home Healthcare
5.6.5 Others
5.7 Australia and New Zealand Anemia in Pregnancy Market by Country
5.7.1 Market Overview
5.7.2 Australia
5.7.3 New Zealand
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 Viatris Inc.
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 Aspen Pharmacare Australia Pty Ltd
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 PharmaCare Laboratories Australia
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 AFT Pharmaceuticals
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Bayer AG
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 A Nelson & Co Ltd
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 BLACKMORES
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 Care Pharma
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 Amgen Inc.
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Hoffmann-La Roche Ltd.
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 AMAG Pharmaceuticals
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Rockwell Medical
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Vifor Pharma Management Ltd.
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Janssen Pharmaceuticals, Inc.
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Teva Pharmaceutical Industries Ltd.
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Australia and New Zealand Anemia in Pregnancy Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
*Additional insights provided are customisable as per client requirements.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us